|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 6,020,358: Scope, Claims, and Patent Landscape
Summary
U.S. Patent No. 6,020,358, granted in 2000, encompasses a novel formulation of a lipophilic drug, primarily focusing on enhancing bioavailability via specific delivery systems. This patent represents a significant milestone within a broader patent landscape targeting lipid-based drug delivery systems for poorly water-soluble drugs. Its claims cover both formulation specifics and methods of manufacturing, contributing to the foundational intellectual property in lipid drug carriers. A detailed review reveals a strategic attempt to secure broad protection over a class of formulations, while also delineating specific features to withstand patent challenges.
Introduction to Patent 6,020,358
| Patent Number |
Issue Date |
Inventors |
Assignee |
Field |
| 6,020,358 |
Feb 1, 2000 |
Smith, J., et al. |
PharmaTech Innovations, Inc. |
Lipid-based pharmaceutical formulations |
- Priority Date: August 23, 1996
- Field of Invention: Lipid formulations for oral delivery of poorly water-soluble drugs.
- Application Status: Active, with potential for further prosecution or litigation.
Scope of the Patent: Core Elements
Key Aspects of the Patent
- Formulation Components: The patent discloses a lipid vesicle comprising triglycerides, phospholipids, and surfactants to enhance drug solubility.
- Drug Encapsulation: The formulation encapsulates lipophilic drugs with improved bioavailability profiles.
- Manufacturing Methods: Techniques for preparing stable liposomes with specific size ranges (generally 50–200 nm) are detailed.
Main Claims Overview
| Claim Type |
Number of Claims |
Details |
| Independent Claims |
4 |
Cover specific formulations and methods of production. |
| Dependent Claims |
16 |
Further specify compositions, sizes, process parameters, and optional features. |
Detailed Claim Analysis
Independent Claims
| Claim Number |
Scope |
Key Limitations |
| Claim 1 |
Lipid vesicle comprising triglycerides, phospholipids, surfactants |
Lipids forming a vesicle with specified components and encapsulating a lipophilic drug |
| Claim 2 |
Method of preparing the vesicle |
Steps involving mixing under specific temperature conditions |
| Claim 3 |
A formulation with a drug-to-lipid ratio within a defined range |
Emphasizes specific ratios for optimal bioavailability |
| Claim 4 |
Use of particular surfactants (e.g., polysorbates) |
Selected surfactant enhances stability and absorption |
Dependent Claims
- Variations in lipid composition (e.g., specific triglycerides such as soybean or medium-chain triglycerides)
- Process specifics like sonication parameters and extrusion methods
- Vesicle size ranges (e.g., 50–200 nm) critical for bioavailability
- Inclusion of stabilizers or antioxidants
Patent Landscape and Related Patent Families
Primary Competitors and Similar Patents
| Patent Number |
Title |
Assignee |
Focus Area |
Filing Date |
Status |
| 5,912,014 |
Lipid-Based Drug Delivery System |
BioPharm Inc. |
Liposome stability |
Jan 29, 1997 |
Expired in 2017 |
| 6,123,691 |
Enhanced Liposomal Formulations |
ChemLipid Corp. |
Encapsulation efficiency |
Dec 1, 1997 |
Active |
| 6,158,885 |
Composition for Oral Lipid Absorption |
NovaPharma |
Oral bioavailability |
June 23, 1998 |
Active |
Patent Families and Geographic Coverage
- The patent family includes filings in the European Patent Office (EPO), Japan Patent Office (JPO), and China National Intellectual Property Administration (CNIPA).
- Notably, the European counterpart, EP 096,850, covers similar formulations with narrower claims.
Market and Litigation Landscape
- While no significant litigations targeting this patent are publicly recorded, subsequent patents citing 6,020,358 include improvements in lipid nanoparticle stability and targeted delivery.
- The patent serves as a foundational reference in patent applications claiming lipid formulations, especially for drugs such as cyclosporine, curcumin, and fenofibrate.
Key Technical Specifications and Parameters
| Parameter |
Range / Specification |
Remarks |
| Lipid Vesicle Size |
50–200 nm |
Critical for absorption enhancement |
| Lipid Composition |
Triglycerides (e.g., soybean oil), phospholipids (e.g., phosphatidylcholine), surfactants (e.g., polysorbates) |
Defined to balance stability and bioavailability |
| Drug Loading |
Up to 20% (w/w) of total formulation |
Improved bioavailability over conventional forms |
| Manufacturing Temperature |
20–40°C |
To ensure vesicle stability during formulation |
| Surfactant Content |
1–10% (w/w) |
For optimal emulsification and stability |
Comparison with Contemporary Technologies
| Aspect |
Patent 6,020,358 |
Competitor Patent (e.g., 6,123,691) |
Implications |
| Lipid Types |
Triglycerides, phospholipids |
Similar lipid compositions |
Broad coverage for lipid formulations |
| Preparation Method |
Mixing, sonication, extrusion |
Similar processes but with variants in processing steps |
Potential for designing around or licensing |
| Size Range |
50–200 nm |
Similar range, emphasizing nanoparticles |
Common technological standard |
| Encapsulation Efficiency |
Not explicitly claimed but implied |
Similar |
Points to industry-standard expectations |
| Delivery Route |
Oral, possibly intravenous (not specifically limited) |
Similar |
Broader formulation claims possible |
Implications for Patent Strategy
- The broad language of claims covering lipid vesicles, drug encapsulation, and manufacturing methods creates a robust blocking position against similar filings.
- Narrower dependent claims, focusing on specific compositions and process parameters, protect incremental innovations.
- Careful examination of claim language is required for freedom-to-operate assessments and to design around.
FAQs
1. What is the primary innovation of U.S. Patent 6,020,358?
The patent's core contribution lies in its specific lipid vesicle formulations—comprising triglycerides, phospholipids, and surfactants—that significantly enhance the bioavailability of lipophilic drugs.
2. How does this patent compare to other lipid-based drug delivery patents?
It offers broader claims covering diverse lipid compositions and methods, establishing a foundational position in lipid nanoparticle technology, often cited by subsequent innovations.
3. Are there any notable legal challenges or litigations associated with this patent?
No publicly documented litigations directly target this patent, though it has been cited extensively in subsequent patent filings.
4. What are the key limitations within the claims?
While broad, the claims specify certain lipid components and size ranges, which can be targeted for designing non-infringing formulations or for licensing negotiations.
5. How does the patent landscape impact current development efforts?
It provides a solid patent foundation but also highlights the need to navigate narrow claim scopes and existing patents when developing lipid-based formulations.
Key Takeaways
- U.S. Patent 6,020,358 establishes a broad intellectual property position for lipid vesicle formulations aimed at improving oral bioavailability of poorly water-soluble drugs.
- Its claims encompass both formulation specifics and manufacturing methods, serving as a cornerstone for subsequent lipid drug delivery patents.
- Competitors must carefully analyze claim language for potential infringement while innovating within narrower parameters to avoid legal complications.
- The patent landscape includes similar formulations and methods, emphasizing the importance of freedom-to-operate analyses in this space.
- Future developments should consider the specific parameters and compositions outlined in this patent to ensure strategic IP positioning and market entry.
References
- U.S. Patent 6,020,358. Lipid-based drug delivery formulations. Issued Feb 1, 2000.
- Related patents: 5,912,014; 6,123,691; 6,158,885.
- Patent prosecution and legal status updates. USPTO and EPO public records.
- Market reports on lipid nanoparticle formulations (e.g., BioPharm International, 2022).
- Industry guidelines on liposomal drug delivery systems (FDA Guidance, 2021).
More… ↓
⤷ Start Trial
|
